Table 2.

Baseline patient characteristics.

Characteristic	Compound Danxiong Granules (n = 67)	Placebo (n = 33)	P value
Mean age/range (years)	55 (31–72)	53 (33–70)	0.478
Sex			0.841
Male	44 (65.7%)	21 (63.6%)
Female	23 (24.3%)	12 (26.4%)
Type of tumor			0.992
Hepatocarcinoma	12 (17.9%)	5 (15.2%)
Renal carcinoma	10 (14.9%)	6 (18.2%)
Lung cancer	22 (32.8%)	11 (33.3%)
Intestinal cancer	21 (31.3%)	10 (30.3%)
Breast cancer	1 (1.5%)	1 (3.0%)
Soft tissue sarcoma	1 (1.5%)
Targeted anticancer agents			0.997
Sorafenib	14 (20.9%)	6 (18.2%)
Sunitinib	8 (11.9%)	5 (15.2%)
Erlotinib	12 (17.9%)	6 (18.2%)
Gefitinib	10 (14.9%)	5 (15.2%)
Cetuximab	21 (31.3%)	10 (30.3%)
Famitinib	2 (3.0%)	1 (3.0%)
Type of skin lesions			0.994
Hand-foot skin reaction	22 (32.8%)	11 (33.3%)
Acneiform eruption	26 (38.8%)	13 (39.4%)
Paronychia	19 (28.9%)	9 (27.3%)
Severity of skin lesions			0.134
Grade I	5 (7.5%)	6 (18.2%)
Grade II	28 (41.8%)	16 (48.5%)
Grade III	34 (50.7%)	11 (33.3%)
Time after the initiation of targeted anticancer therapies	23 ± 10 (days)	24 ± 14 (days)	0.700